Lamotrigine for bipolar disorder: translating research into clinical practice

References

• Weissman MM, Bland RC, Canino GJ et al Cross-national epidemiology of major depression and bipolar disorder. JAMA 276, 293–299 (1996).
   PubMed Web of Science ®Google Scholar
• Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J. Affect. Disord 50,143–151 (1998).
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: global burden disease study. Lancet 349,1436–1442 (1997).
   PubMed Web of Science ®Google Scholar
• Harris EC, Barroclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br. Psychiatry170,205–228 (1997).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ et al The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. PTchiatry59(6), 530–537 (2002).
   Google Scholar
• Judd LL, Akiskal HS, Schettler PJ et al A prospective Investigation of the natural history of the long-term weekly symptomatic status of bipolar disorder II. Arch. Gen. PTchiatry60, 261–269 (2003).
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Jamison KR. Manic- depressive illness. Oxford University Press, New York, USA (1990).
   Google Scholar
• Yatham LN. Efficacy of atypical antipsychotics in mood disorders. Jan. Bychopharmacol 23(3 Suppl. 1), S9—S14 (2003).
   Google Scholar
• Kasper S. Issues in the treatment of bipolar disorder. Eur. Neuropsychopharmacol 13, S37—S42 (2003).
   Google Scholar
• Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. PTchiatry161, 217–222 (2004).
   Google Scholar
• Calabrese JR, Rapport DJ, Kemmel SE, Shelton MD. Controlled trials in bipolar I depression: focus on switch rates and efficacy. Eur. Neumpsychopharmacol 9\(Suppl. 4), S109—S112 (1999).
   Google Scholar
• Keck PE, Nelson EB, McElroy SL. Advances in the pharmacologic treatment of bipolar depression. Biol. Psychiatry 53, 671–679 (2003).
   Google Scholar
• Tohen M, Vieta E, Calabrese J et al Efficacy of olanzapine and olanzapine—fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60,1079–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Malhi GS, Mitchell PB. The expanding pharmacopeia for bipolar disorder. CNS Drugs 17(1), 9–25 (2003).
   PubMed Web of Science ®Google Scholar
• Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-ontreatment with lamotrigine in partial epilepsy. Epilepsia 34,312–322 (1993).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RMA, Bowden CL, Perlis RH et al. Practice guidelines for the treatment of patients with bipolar disorder. Am. J. Psychiatry 159 (Suppl. 4), 4–50 (2002).
   Google Scholar
• Burstein AH. Lamotrigine. Pharmacothempy15,129–143 (1995).
   PubMed Web of Science ®Google Scholar
• Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur j Pharmacology 307, 113–116 (1996).
   PubMed Web of Science ®Google Scholar
• Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Synapse 29,355–362 (1998).
   Google Scholar
• Ketter TA, Frye MA, Cora-Locatelli G et al Metabolism and excretion of mood stabilizers and new anticonvulsants. Mole. Neurobiol 19(4), 511–532 (1999).
   Web of Science ®Google Scholar
• Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur Pharmacology358, 19–24 (1998).
   PubMed Web of Science ®Google Scholar
• Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res. 13,107–112 (1992).
   Google Scholar
• Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy Neuropsychobiology 38,119–130 (1998).
   Google Scholar
• Cunningham MO, Jones RSH. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro Neuropharmacology39, 2139–2146 (2000).
   Google Scholar
• Ketter TA, Wang PW, Becker OV,
   Google Scholar
• •Nowakowska C, Yang YS. The diverse roles of anticonvulsants in bipolar disorders. Ann. Clin. Psychiatry 15 (2), 95–108 (2003) .
   Google Scholar
• Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 43(4), 365–385 (2002).
   PubMed Web of Science ®Google Scholar
• Garnett WR. Lamotrigine: pharmacokinetics. J. Child. Neurology 12\(Suppl. 1), S10—S15 (1997)
   Google Scholar
• Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br. Clin. Pharmacology43, 457–465 (1997).
   PubMed Web of Science ®Google Scholar
• Chan V, Morris RG, Ilett KF, Tett SE. Population pharmacokinetics of lamotrigine. Ther. Drug- Monit. 23, 630–635 (2001).
   PubMed Web of Science ®Google Scholar
• Hurley SC. Lamotrigine update and its use
   Google Scholar
• •in mood disorders. Ann. Pharmacother. 36, 860–873 (2003).
   Google Scholar
• Fischer JH. Drug interactions with
   Google Scholar
• •antiepileptic agents. CNS News Special Edition, 30–38 (2001).
   Google Scholar
• Ramsay RE, Pellock JM, Garnett et al Pharmacokinetics and safety of lamotrigine (Lamictala) in patients with epilepsy. Epilepsy Res. 10,191–200 (1991).
   PubMed Web of Science ®Google Scholar
• Wooton R, Soul-Lawton J, Rolan PE, Sheung CT, Cooper JD, Posner J. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. BE j Clin. Pharmacology 43, 23–27 (1997).
   PubMed Web of Science ®Google Scholar
• Marcellin P, de Bony F, Garret C et al Influence of cirrhosis on lamotrigine pharmacokinetics. BE j Clin. Pharmacology 51(5), 410–414 (2001).
   Web of Science ®Google Scholar
• Bourgeois BE Pharmacokinetic properties of current anti-epileptic drugs: what improvements are needed?. Neurology 55(11 Suppl. 3), S11—S16 (2000).
   Google Scholar
• Kanner AM, Balabanov A. Valproate: a practical review of its uses in neurological and psychiatric disorders. Expert Rev Neurotherapeutics2(2), 151–165 (2002).
   PubMedGoogle Scholar
• Guberman AH, Besag FMC, Brodie MJ et al Lamotrigine-associated rash: risk/ benefit considerations in adults and children. Epilepsia 40,985–991 (1999).
   PubMed Web of Science ®Google Scholar
• Crawford P Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16(4), 263–272 (2002).
   Google Scholar
• Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 47, 151–154 (2001).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, McElroy SL et al Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am I Bychiatry156,1019–1023 (1999).
   PubMed Web of Science ®Google Scholar
• Suppes T, Brown ES, McElroy SL et al Lamotrigine for the teratment of bipolar disorder: a clincal case series. J. Affect. Disord 53,95–98 (1999).
   PubMed Web of Science ®Google Scholar
• Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized control trial. Ann. Clin. Psychiatry12,5–10 (2000).
   Google Scholar
• Yatham LN. Kusumakar V Calabrese JR.
   Google Scholar
• •Rao R. Scarrow G. Kroeker G. Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. j Clin. PTchiatry 63 (4), 275–283 (2002) .
   Google Scholar
• Anand A, Oren DA, Berman A etal. Lamotrigine treatment of lithium failure outpatient mania: a double-blind placebo-controlled trial. Bipo/arDisar/. 1,23 (1999).
   Google Scholar
• Calabrese JR, Bowden CL, Sachs GS,
   Google Scholar
• •Ascher JA, Monaghan E, Rudd ED. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J. Clin. Psychiatry 60,79-88 (1999).
   Google Scholar
• Bowden CL, Calabrese JR, Asher J et al Spectrum of efficacy of lamotrigine in bipolar disorder: overview of double-blind placebo-controlled studies. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology 10–14 December. San Juan, Puerto Rico. (2000).
   Google Scholar
• Frye MA, Ketter TA, Kimbrell TA et al A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. PTchopharmacol 20,607–614 (2000).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS et al
   Google Scholar
• •A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar 1 disorder. J. Clin. Psychiatry September 64(9), 1013–1024 (2003).
   Google Scholar
• Bowden CL, Calabrese JR, Sachs GS
   Google Scholar
• •et al A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar 1 disorder. Arch. Gen. Psychiatry 60(4), 392–400 (2003).
   Google Scholar
• Goodwin GM. Geddes JR. Latest
   Google Scholar
• ••maintenance data on lithium in bipolar disorder. Eur Neuropsychopharmacol 13(Suppl. 2), S51—S55 (2003).
   Google Scholar
• Calabrese JR, Suppes T, Bowden CL et al
   Google Scholar
• ••A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Jan. Psychiatry 61(11), 841–850 (2000).
   Google Scholar
• GlaxoSmithKline. Study 611 (2003).
   Google Scholar
• Culy CR, Goa KL. Lamotrigine: a review of its use in childhood epilepsy. Paediatric Drugs2, 299–330 (2000).
   PubMedGoogle Scholar
• Wong IC, Mawer GE, Sander JW. Factors
   Google Scholar
• ••influencing the incidence of lamotrigine- related skin rash. Ann. Pharmacotheraphy 33,1037-1042 (1999).
   Google Scholar
• Sterker M, Berroushot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. hit. j Clin Phannacol Therapeuths33, 595–597 (1995).
   Google Scholar
• Hebert AA, Ralston JR Cutaneous reactions to anticonvulsants. j Clin. Psychiatry 62 (Suppl. 14), 22–26 (2001).
   Google Scholar
• Botts SR, Raskind J. Gabapentin and lamotrigine in bipolar disorder. Am. J. Health Syst. Pharm. 56(19), 1939–1944 (1999).
   Google Scholar
• Macdonald KJ, Young LT Newer antiepileptic drugs in bipolar disorder. CNS Drugs 16(8), 549–562 (2002).
   PubMed Web of Science ®Google Scholar
• Macritchie KAN, Geddes JR, Watson SW Young AH. Lamotrigine in the treatment of acute affective episodes in bipolar disorder. Cochrane Database Syst. Rev 3 (2003).
   Google Scholar
• Tennis P, Eldridge RR. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 43 (10), 1161–1167 (2002).
   PubMed Web of Science ®Google Scholar
• Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. Jan. Psychiatry 63, 737–741 (2002).
   Google Scholar
• Barbosa L, Berk M, Vorster M. A double- blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J. Clin. Psychiatry 64, 403–407 (2003).
   Google Scholar
• Rocha FL, Ham C. Lamotrigine augmentation in unipolar depression. Int. Clin. Psychopharmacol 18,97–99 (2003).
   PubMed Web of Science ®Google Scholar
• Dursun SM, Deakin JE Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Psychopharmaco1.15, 297–301 (2001).
   Google Scholar
• Dursun SM. McIntosh D. Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch. Gen. Psychiatry56, 950 (1999).
   PubMed Web of Science ®Google Scholar